Clarity Pharmaceuticals (ASX:CU6) ROE % Adjusted to Book Value : -11.73% (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Clarity Pharmaceuticals ROE % Adjusted to Book Value?

Clarity Pharmaceuticals's ROE % for the quarter that ended in Dec. 2023 was -56.29%. Clarity Pharmaceuticals's PB Ratio for the quarter that ended in Dec. 2023 was 4.80. Clarity Pharmaceuticals's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2023 was -11.73%.

Clarity Pharmaceuticals ROE % Adjusted to Book Value Historical Data

The historical data trend for Clarity Pharmaceuticals's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Clarity Pharmaceuticals ROE % Adjusted to Book Value Chart

Clarity Pharmaceuticals Annual Data

Trend

Jun22

Jun23

ROE % Adjusted to Book Value

-18.01

-11.55

Clarity Pharmaceuticals Semi-Annual Data
	Dec20	Dec21	Jun22	Dec22	Jun23	Dec23
ROE % Adjusted to Book Value	Get a 7-Day Free Trial			-19.69	-14.52	-16.05	-13.41	-11.73

Competitive Comparison of Clarity Pharmaceuticals's ROE % Adjusted to Book Value

For the Biotechnology subindustry, Clarity Pharmaceuticals's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Clarity Pharmaceuticals's ROE % Adjusted to Book Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Clarity Pharmaceuticals's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Clarity Pharmaceuticals's ROE % Adjusted to Book Value falls into.

Clarity Pharmaceuticals ROE % Adjusted to Book Value Calculation

Clarity Pharmaceuticals's ROE % Adjusted to Book Value for the fiscal year that ended in Jun. 2023 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-30.48%	/	2.64
	=	-11.55%

Clarity Pharmaceuticals's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-56.29%	/	4.80
	=	-11.73%

Clarity Pharmaceuticals ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Clarity Pharmaceuticals's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Clarity Pharmaceuticals (ASX:CU6) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Clarity Pharmaceuticals Ltd (ASX:CU6) » Definitions » ROE % Adjusted to Book Value

Comparable Companies

Traded in Other Exchanges

CLRPF:USA

Address

4 Cornwallis Street, National Innovation Centre, Eveleigh, Sydney, NSW, AUS, 2015

Website

https://www.claritypharmaceuticals.com

Clarity Pharmaceuticals Ltd is a clinical-stage radiopharmaceutical company developing next-generation theranostic (therapy and imaging) products, based on its platform SAR Technology. The SAR technology is ideally suited for use with copper isotopes, enabling superior imaging and therapeutic characteristics of radiopharmaceutical products and addressing the current manufacturing and logistical limitations in the growth of the radiopharmaceutical sector in oncology.

Clarity Pharmaceuticals (ASX:CU6) Headlines

No Headlines